MI-503 NEW
| Price | $123 | $198 | $372 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: MI-503 | CAS No.: 1857417-13-0 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | MI-503 |
| Description | MI-503 is an efficient and selective Menin-MLL inhibitor with an IC50 of 14.7 nM. In human MLL leukemia cell lines, MI-503 has a significant growth inhibition effect (GI = 250 nM-570 nM). |
| Cell Research | Leukemia cells are treated with MI-503 or 0.25% DMSO and cultured at 37 °C for 7 days. Media is changed on day 4, viable cell numbers are restored to the original concentration and MI-503 are re-supplied. MTT cell proliferation assay kit is then employed, and plates are read for absorbance at 570 nm using a microplate reader. |
| Animal Research | For efficacy studies in MV4;11 subcutaneous xenograft mice model, 5×10^6 cells are injected into the 4-6 week old female BALB/c nude mice. Treatment is started when the tumor size reached ~100 mm^3. Vehicle (25% DMSO, 25% PEG400, 50% PBS) or compounds (MI-463 or MI-503) are administrated once daily at designated doses using i.p. injections. |
| In vitro | Treatment of murine bone marrow cells (BMC) transformed with the mLL-AF9 oncogene with MI-503 results in substantial growth inhibition (GI50: 0.22 μM). The cell growth inhibitory effect of MI-503 is time-dependent, with a pronounced effect achieved after 7-10 days of treatment. |
| In vivo | Following a single intravenous or oral administration, MI-503 rapidly attains high concentrations in peripheral blood and demonstrates significant oral bioavailability (75%). This compound effectively suppresses tumor growth through daily intraperitoneal (i.p.) doses, leading to an over 80% decrease in MV4;11 tumor volume, including complete regression in two mice. Continuous treatment over ten days notably delays the progression of mLL leukemia and substantially lowers the leukemia tumor burden in mice. Additionally, combined use of MI-503 and MI-463 significantly diminishes the expression of Hoxa9 and Meis1, indicating a potent antitumor activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 7.75 mg/mL (13.73 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 77.5 mg/mL (137.26 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7.75 mg/mL (13.73 mM), Solution. H2O : Insoluble |
| Keywords | MI-503 | MI503 | MI 503 | Menin-MLL | Inhibitor | inhibit | HistoneMethyltransferase | Histone Methyltransferase | EpigeneticReaderDomain | Epigenetic Reader Domain |
| Inhibitors Related | MAK-683 hydrochloride | ABBV-744 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | Tazemetostat | Piribedil | 5-Ph-IAA | Curcumin | EPZ015666 | iso-Azalansta | Naphthol AS-E | MRTX-1719 | JQ-1 (carboxylic acid) |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Chromatin Modification Compound Library | Hematonosis Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2680.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $35.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-09 | |
| $20.00 |
Wuhan Mulei New Material Technology Co. Ltd
|
2022-02-24 | ||
|
Hubei Chuchang Biotech Co., Ltd.
|
2025-03-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY